| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 9989 from our risk checks.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.74 |
| 52 Week High | CN¥4.15 |
| 52 Week Low | CN¥2.39 |
| Beta | 0.42 |
| 11 Month Change | 8.72% |
| 3 Month Change | 14.72% |
| 1 Year Change | -8.11% |
| 33 Year Change | -55.74% |
| 5 Year Change | n/a |
| Change since IPO | -76.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9989 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 12.3% | 8.8% | 10.9% |
| 1Y | -8.1% | 18.4% | 13.4% |
Return vs Industry: 9989 underperformed the Hong Kong Pharmaceuticals industry which returned 18.4% over the past year.
Return vs Market: 9989 underperformed the Hong Kong Market which returned 13.4% over the past year.
Price Volatility
| 9989 volatility | |
|---|---|
| 9989 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in HK Market | 13.7% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 9989 has not had significant price volatility in the past 3 months.
Volatility Over Time: 9989's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,080 | Yu Shan | www.hepalink.com |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 9989 fundamental statistics | |
|---|---|
| Market cap | HK$15.20b |
| Earnings (TTM) | -HK$269.27m |
| Revenue (TTM) | HK$6.17b |
2.7x
P/S Ratio-62.8x
P/E RatioIs 9989 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9989 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.57b |
| Cost of Revenue | CN¥4.58b |
| Gross Profit | CN¥985.69m |
| Other Expenses | CN¥1.23b |
| Earnings | -CN¥242.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 17.70% |
| Net Profit Margin | -4.36% |
| Debt/Equity Ratio | 36.8% |
How did 9989 perform over the long term?
See historical performance and comparison